We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest trading session, Amgen (AMGN - Free Report) closed at $371.47, marking a +1.48% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.21%. Meanwhile, the Dow experienced a drop of 0.97%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Prior to today's trading, shares of the world's largest biotech drugmaker had gained 4.16% outpaced the Medical sector's gain of 3.97% and the S&P 500's gain of 0.42%.
The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings report is expected on August 4, 2026. It is anticipated that the company will report an EPS of $5.6, marking a 6.98% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.45 billion, up 2.94% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $22.31 per share and a revenue of $37.73 billion, representing changes of +2.15% and +2.67%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.34% downward. Amgen is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note Amgen's current valuation metrics, including its Forward P/E ratio of 16.41. Its industry sports an average Forward P/E of 18.84, so one might conclude that Amgen is trading at a discount comparatively.
Also, we should mention that AMGN has a PEG ratio of 3.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.54 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Amgen (AMGN - Free Report) closed at $371.47, marking a +1.48% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.21%. Meanwhile, the Dow experienced a drop of 0.97%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Prior to today's trading, shares of the world's largest biotech drugmaker had gained 4.16% outpaced the Medical sector's gain of 3.97% and the S&P 500's gain of 0.42%.
The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings report is expected on August 4, 2026. It is anticipated that the company will report an EPS of $5.6, marking a 6.98% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.45 billion, up 2.94% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $22.31 per share and a revenue of $37.73 billion, representing changes of +2.15% and +2.67%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.34% downward. Amgen is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note Amgen's current valuation metrics, including its Forward P/E ratio of 16.41. Its industry sports an average Forward P/E of 18.84, so one might conclude that Amgen is trading at a discount comparatively.
Also, we should mention that AMGN has a PEG ratio of 3.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.54 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.